Kevin Charles Gorman Neurocrine Biosciences Inc (NBIX) insider trading activity

Kevin Charles Gorman is Director of NEUROCRINE BIOSCIENCES INC. Currently has a direct ownership of 524,209 shares of NBIX, which is worth approximately $60.3 Million. The most recent transaction as insider was on Feb 13, 2025, when has been sold 5,844 shares (Common Stock) at a price of $116.69 per share, resulting in proceeds of $681,936. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 524K

1.87% 3M change

1.87% 12M change

Total Value Held $60.3 Million

KEVIN CHARLES GORMAN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 13 2025	SELL Open market or private sale	$681,936 $116.69 p/Share	5,844 Reduced 1.1%	524,209 Common Stock
Feb 13 2025	BUY Exercise of conversion of derivative security	-	10,979 Added 2.04%	527,221 Common Stock
Feb 10 2025	SELL Open market or private sale	$269,173 $118.37 p/Share	2,274 Reduced 0.44%	519,074 Common Stock
Feb 08 2025	BUY Exercise of conversion of derivative security	-	4,318 Added 0.82%	521,348 Common Stock
Jan 31 2025	SELL Open market or private sale	$413,954 $152.92 p/Share	2,707 Reduced 0.52%	517,030 Common Stock
Jan 31 2025	BUY Exercise of conversion of derivative security	-	5,141 Added 0.98%	519,737 Common Stock
Jan 27 2025	SELL Open market or private sale	$21,836,853 $149.46 p/Share	146,105 Reduced 22.11%	514,596 Common Stock
Jan 27 2025	BUY Exercise of conversion of derivative security	$4,820,003 $32.99 p/Share	146,105 Added 18.11%	660,701 Common Stock
Feb 13 2024	SELL Open market or private sale	$376,712 $133.02 p/Share	2,832 Reduced 0.55%	514,596 Common Stock
Feb 13 2024	BUY Exercise of conversion of derivative security	$201,665 $39.62 p/Share	5,090 Added 0.98%	512,052 Common Stock
Feb 08 2024	SELL Open market or private sale	$305,057 $134.15 p/Share	2,274 Reduced 0.45%	506,962 Common Stock
Feb 06 2024	SELL Open market or private sale	$432,227 $142.18 p/Share	3,040 Reduced 0.6%	504,919 Common Stock
Jan 31 2024	SELL Open market or private sale	$380,847 $140.69 p/Share	2,707 Reduced 0.54%	502,188 Common Stock
Jan 09 2024	SELL Open market or private sale	$8,311,702 $134.01 p/Share	62,023 Reduced 11.04%	499,754 Common Stock
Jan 09 2024	BUY Exercise of conversion of derivative security	$1,215,030 $19.59 p/Share	62,023 Added 9.94%	561,777 Common Stock
Jan 08 2024	SELL Open market or private sale	$14,016,787 $132.44 p/Share	105,835 Reduced 17.48%	499,754 Common Stock
Jan 08 2024	BUY Exercise of conversion of derivative security	$2,073,307 $19.59 p/Share	105,835 Added 14.88%	605,589 Common Stock
Aug 21 2023	SELL Open market or private sale	$1,001,827 $107.4 p/Share	9,328 Reduced 1.83%	499,754 Common Stock
Feb 08 2023	SELL Open market or private sale	$237,178 $104.3 p/Share	2,274 Reduced 0.46%	491,365 Common Stock
Feb 07 2023	SELL Open market or private sale	$2,429,240 $102.37 p/Share	23,730 Reduced 4.63%	489,322 Common Stock
Feb 06 2023	SELL Open market or private sale	$321,267 $105.68 p/Share	3,040 Reduced 0.65%	468,008 Common Stock
Jan 31 2023	SELL Open market or private sale	$297,986 $110.08 p/Share	2,707 Reduced 0.58%	465,278 Common Stock
Feb 08 2022	SELL Open market or private sale	$180,760 $79.49 p/Share	2,274 Reduced 0.49%	462,844 Common Stock
Feb 07 2022	SELL Open market or private sale	$703,942 $80.82 p/Share	8,710 Reduced 1.86%	460,801 Common Stock
Feb 08 2021	SELL Open market or private sale	$1,221,906 $116.75 p/Share	10,466 Reduced 2.26%	452,972 Common Stock

Also insider at

XNCR

Xencor Inc Healthcare

Director

KCG